DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice.
DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice.
Clin Ther. 2019 Jun 01;:
Authors: Spanopoulos D, Busse M, Webb J, Tebboth A, Gollop ND, Marcus MW
Abstract
Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests. This cross-sectional study examines all DPP-4 inhibitor initiations that require dose adjustment and the dose selection using data from UK general practice. Results indicate that 34% of patients taking a nonlinagliptin DPP-4 inhibitor were given a higher dose and 11% a lower dose than specified in the Summary of Product Characteristics. This reinforces the deviation from Summary of Product Characteristics prescription of DPP-4 inhibitors identified in earlier studies despite improvement in compatibility with routine reporting. (Clin Ther. 2019; XX:XXX-XXX) © 2019 Elsevier HS Journals, Inc.
PMID: 31164243 [PubMed - as supplied by publisher]
Source: Clinical Therapeutics - Category: Drugs & Pharmacology Authors: Spanopoulos D, Busse M, Webb J, Tebboth A, Gollop ND, Marcus MW Tags: Clin Ther Source Type: research
More News: Drugs & Pharmacology | General Practices | Januvia | Laboratory Medicine | Primary Care | Study